NCT00669890: Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML |
|
|
| Terminated | 1 | 12 | US | Gemtuzumab Ozogamicin, Gemtuzumab, Busulfan, Busulfex, Cyclophosphamide, Endoxan, Cytoxan, Thymoglobulin, ATG, Tacrolimus, FK506, Mycophenolate Mofetil, MMF, Methotrexate, MTX | New York Medical College | Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome | 12/12 | 12/13 | | |
